Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Topical PDE4 Inhibitor for Morphea - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if crisaborole 2% will soften the skin with scleroderma and to see if it can be a safe and helpful treatment for morphea.
What is the Condition Being Studied?

Who Can Participate in the Study?

Adults who:
- Have morphea
- Are not on a treatment to make your immune system work better. (If you are on this treatment, you are willing to stop immune system treatment right before and during the study.)
- Do not have a kidney disease
- Are not pregnant

Age Group

What is Involved?

If you choose to join this study, you will:
- Have 4 visits in 12 weeks
- Have the option to have a 5th visit at 20 weeks
- Be asked to apply crisaborole 2% ointment to your morphea 2 times a day for 12 weeks
- Have your skin looked at by the study doctor
- Answer questionnaires
- Have a sample of skin tissue taken from part of your morphea
- Have a skin ultrasound
- Have your morphea photographed

Study Details

Full Title
Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
Principal Investigator
Protocol Number
IRB: PRO00086947
NCT: NCT03351114
Phase II
Contact the Duke Recruitment Innovation Center